• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

    10/29/24 7:30:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email

    DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

    To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.

    A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until November 4, 2025.

    About Bioventus

    Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

    Investor and Media Inquiries:

    Dave Crawford

    919-474-6787

    [email protected]  



    Primary Logo

    Get the next $BVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    3/15/2022$30.00Buy
    Craig Hallum
    3/11/2022$20.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bioventus upgraded by Analyst with a new price target

      Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

      12/17/24 7:32:13 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00

      12/7/23 6:14:32 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Bioventus from Hold to Buy and set a new price target of $6.00 from $4.00 previously

      8/9/23 7:43:55 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      8/20/24 6:16:00 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives.

      1/7/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. converted options into 7,575 shares, increasing direct ownership by 11% to 79,620 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/10/25 5:49:16 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Bartholdson John A. converted options into 26,493 shares, increasing direct ownership by 58% to 72,045 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/5/25 9:22:27 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Sutter Martin P converted options into 26,493 shares, increasing direct ownership by 45% to 85,241 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/4/25 9:30:50 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care